Convé plc (Convé), the specialty pharmaceutical company, is pleased to announce the appointment of Dr David Glover (MRCP FFPM) as a Non-Executive Director of the Company.
David is a very experienced physician and senior manager with over 20 years experience of clinical development and research in pharmaceutical and biotechnology companies. He held senior positions with Merck Sharp and Dohme and Schering Plough before joining Cambridge Antibody Technology (CAT) Group plc initially as Medical Director. In his ten year career with CAT he progressed to become Chief Medical Officer and Executive Director. At CAT David played a major role in helping the company to raise over £180 million through private and public raisings. David's pharmaceutical industry experience spans all phases of preclinical and clinical development programs, on many different chemical and biological drugs in many therapeutic areas, through to regulatory approvals, right through to product launches and ongoing medical-marketing support. John Dawson, CEO of Convé, commented: "I am delighted that David has joined the board of Convé. David's extensive experience of developing products through research, clinical development and regulatory approval, will be invaluable as we progress our clinical development program."
